Bioforce Nanosciences Holdings Inc (BFNH) Financial Statements (2026 and earlier)

Company Profile

Business Address 2020 GENERAL BOOTH BLVD
VIRGINIA BEACH, VA 23454
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments78686263873411,10539,865
Cash and cash equivalent78686263873411,10539,865
Prepaid expense     40 
Total current assets:78686263873411,14539,865
Noncurrent Assets
TOTAL ASSETS:78686263873411,14539,865
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:11,8368,8362,6493986,3135,090
Other undisclosed accounts payable and accrued liabilities11,8368,8362,6493986,3135,090
Due to related parties✕✕✕✕ 116,17867,166
Other undisclosed current liabilities607,4932,293,6181,817,2191,347,613750,517327,517
Total current liabilities:619,3292,302,4541,819,8681,348,011873,008399,773
Noncurrent Liabilities
Total liabilities:619,3292,302,4541,819,8681,348,011873,008399,773
Equity
Equity, attributable to parent(618,543)(2,301,592)(1,819,230)(1,347,277)(861,863)(359,908)
Common stock33,52229,27229,27229,27229,27229,272
Additional paid in capital161,760,052158,789,302158,781,227158,781,227158,781,127158,781,127
Accumulated deficit(162,412,117)(161,120,166)(160,629,729)(160,157,776)(159,672,262)(159,170,307)
Total equity:(618,543)(2,301,592)(1,819,230)(1,347,277)(861,863)(359,908)
TOTAL LIABILITIES AND EQUITY:78686263873411,14539,865

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(489,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)
Operating loss:(489,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)
Interest and debt expense802,000     
Income (loss) from continuing operations before equity method investments, income taxes:312,049(490,437)(471,953)(485,514)(501,955)(158,408,555)
Other undisclosed loss from continuing operations before income taxes(802,000)     
Income (loss) from continuing operations:(489,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(501,955)(158,408,555)
Net income (loss):(489,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)
Other undisclosed net loss attributable to parent(802,000)     
Net loss available to common stockholders, diluted:(1,291,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(489,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)
Comprehensive income (loss), net of tax, attributable to parent:(489,951)(490,437)(471,953)(485,514)(501,955)(158,408,555)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: